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Medication adherence is a well-recognized problem in the management of patients with
chronic diseases needing a long-term pharmacotherapy. While fighting against non-
adherence, an important question frequently arises, i.e., how much adherence is enough
to obtain the full treatment benefits? Most studies having attempted to answer this
question have used large pharmacy records and health care databases to quantify the
percentage of days covered by the prescribed treatment and hence deduce a threshold
below which there appears to be fewer benefits from therapy. In the present paper, the
use of data obtained using electronic monitoring of adherence is discussed as another
means to assess adherence thresholds with a particular emphasis on hypertension. The
data show that even with the use of electronic monitoring of adherence, which provides
a comprehensive dosing history, it is extremely difficult to define an adherence threshold
in hypertension. This is due to many factors that need to be taken into account,
including not only the pattern of patients’ adherence and their clinical and environmental
characteristics, but also the pharmacological characteristics of the prescribed drugs,
the severity of the disease and many others. To determine adherence cut-offs more
precisely, specific protocols should be designed to answer the question in various clinical
conditions. These protocols should be conducted in well-defined patients’ groups, they
should use the most reliable methods to measure adherence providing if possible a
detailed dosing history perhaps combined with drugs levels in blood or urine. These
studies should also choose the best methods to measure clinical endpoints, such
as ambulatory blood pressure monitoring or home blood pressure in the case of
hypertension. One important aspect is that datasets should be solid and large enough
to be able to analyze adherence data as a continuous variable using newly developed
mathematical models including new metrics catching the complexity of adherence. The
rapid development of new technologies like devices, connectivity, and analytics, will
probably provide new solutions to improve our ability to define valid and clinically useful
adherence thresholds in various therapeutic areas.
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INTRODUCTION
To maintain a high level of medication adherence
over years is one the most difficult challenge in the
management of medical conditions, which need chronic
ambulatory pharmacotherapies. This issue is even
more relevant in asymptomatic conditions such as the
treatment of cardiovascular risk factors. Indeed, in patients
with hypertension or dyslipidaemia, non-adherence to
medications is highly prevalent (Naderi et al., 2012). This
is certainly one reason why many patients with a high
cardiovascular risk do not benefit from otherwise effective
medicines.
According to the last official consensus definition of
medication adherence, adherence is the process by which
patients take their medications as prescribed (Vrijens et al.,
2012). This process implies three components: the initiation,
the implementation, and the discontinuation. The initiation
process is crucial and non-initiation may affect up to 20%
of patients (Fischer et al., 2011). In hypertension, depending
on its severity, non-initiation may have important clinical
consequences with a high risk of serious events such as stroke
or heart failure. At this stage, the main unresolved questions
are: why are patients not starting their treatment and how
quickly should patients initiate their therapy? However, in
clinical practice, the implementation, representing the extent
to which the patients’ actual dosing is in accordance with
prescribed dosing regimen, and the persistence, which represents
the time between initiation and the last dose, are probably
the most critical parameters to estimate drugs utilization
in relation with their clinical impact. Therefore, medication
persistence will be the main parameter considered in our
discussion.
Among all terminologies and parameters used to define
adherence to medications, none enables to answer the
important clinical question, i.e., how much medication
adherence is enough. This is indeed a very difficult question
to answer because the benefits of a good adherence may
depend on several factors. These include: the pattern of
non-adherence, the pharmacology of drugs, the type and
characteristics of diseases (severity, duration,..), the outcome
measures chosen to assess the clinical benefits (for example
intermediate endpoints or hospitalizations or hard endpoints
such as stroke, heart failure, or death), and of course the
characteristics of patients and their social and familial
environment.
In this article, the concept of “how much medication
adherence is enough” is discussed in the light of two different
approaches. The first is the use of data collected from electronic
health records or pharmacy dispensing databases, which allow
quantifying adherence as treatment discontinuation or overall
persistence rate. The second is the use of data obtained from
electronic monitoring of medication adherence using for example
the Medication Event Monitoring System (MEMS), which
provides a dosing history with a real-time capture of the dosing
events.
HEALTH CARE AND PHARMACY
DATABASES AND ADHERENCE
THRESHOLDS
In the last 10–15 years, many large regional and national
health care administrative databases based on medical registries
and pharmacy records have been created enabling to follow
medications’ prescriptions and their discontinuation, i,e., failure
to renew a prescription for a prolonged time interval, in
large groups of individuals over years. With these data, it has
become possible to assess indirectly the medication persistence
calculating the medication possession ratio (MPR), which is
the ratio of the number of drug doses taken to the number
of doses prescribed over a given time period (Steiner and
Prochazka, 1997), as well as the percentage of days covered
(PDC) by the prescriptions. In the field of cardiovascular
medicine, several analyses have demonstrated that higher MPR
or PDC are associated with a lower mortality (Simpson et al.,
2006) and a reduced risk of cardiovascular complications
such as stroke, congestive heart failure, or coronary events
(Perreault et al., 2008, 2009, 2010, 2012; Mazzaglia et al., 2009;
Corrao et al., 2010, 2011, 2015; Degli Esposti et al., 2011;
Qvarnstrom et al., 2013; Xu et al., 2017; Yang et al.,
2017). Conversely, interrupting cardiovascular protecting drugs
is associated with an increasing risk of developing such
complications (Corrao et al., 2012). Similar observations have
been done in other fields of medicine such as HIV therapies
(Paterson et al., 2000), immunosuppression in transplantation
(Dobbels et al., 2004) and recently oncology (Bhatia et al., 2015).
In almost all adherence analyses based on MPR or PDC,
patients are distributed in arbitrarily defined categories of
adherence such as for example: ≥80% and <80%, or ≥80%,
≤50 to <80% and <50% without a specific scientific rational or
meaning for these choices. With such categorizations, authors
usually find a dose-effect relationship between the percentage
of adherence and chosen endpoints, a higher adherence being
associated with better outcomes as discussed above. Figure 1
illustrates one example of the relationship between adherence
to antihypertensive therapy and the risk of coronary and
cerebrovascular events in 445,356 patients from the Lombardy
database (Corrao et al., 2011). However, it is interesting to note
that almost all these studies used the arbitrary threshold of 80%
to characterize a good adherence as proposed by R.B Haynes in
his book on adherence published together with DL. Sackett in
1976 (Haynes, 1976). Yet, in addition to being arbitrarily defined,
this threshold is not always supported by research documenting
the appropriateness of cutoffs for specific medication classes or
diseases (Cramer et al., 2008). Thus, in five cohorts of patients
diagnosed with schizophrenia, diabetes, hypertension, congestive
heart failure, or hyperlipidemia, the optimal cut-off adherence
values for the MPR and PDC in predicting disease-specific
hospitalizations across the five cohorts ranged from 0.58 to 0.85
(Karve et al., 2009). In lipid management, direct comparisons
of the 0.9–1.0 MPR category versus the 0.8–0.89 MPR category
demonstrated a significant increase in odds of achieving 25% or
more reduction in total cholesterol, LDL and non-HDL in the
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FIGURE 1 | Dose-dependent effect of adherence with antihypertensive drug therapy on the reduction in hazard ratio of coronary and cerebrovascular outcomes.
Analysis of the Lombardy database. Adherence measured according to the proportion of days of observation covered by antihypertensive medication. Adherence
levels are the following: very low coverage: <25%; low coverage: 26–50%; intermediate coverage: 51–75%; and high coverage: >75%. Adapted from Corrao et al.
(2011).
highest category (Watanabe et al., 2013). In fact, estimations of
the relationship between adherence and outcomes based on the
MPR or the PDC have several limitations. Firstly, most studies
have not been designed with the goal of defining prospectively
an adherence threshold. Hence, values remain rough estimates.
Secondly, the methods used to measure adherence are very
indirect and authors have no idea on what patients actually
did with their medications during the period of observation.
Thirdly, authors do not take into account that a mean of 80%
can represent several different patterns of adherence such as
missing one day on five or one month on five, the clinical impact
being very different in each condition. Fourthly, the quality of
outcome measurements is not always optimal. For example, in
hypertension, the main outcome is often office blood pressure
measured only once by physicians. Home blood pressure or 24 h
ambulatory blood pressure monitoring would be more reliable
and hence appropriate. At last, several different methodologies
were used to estimate the cut-off points including multiple
logistic regressions, univariate logistic regression models, and
calculation of the upper most left point of the receiver operating
curve corresponding to the maximum specificity and sensitivity
of the adherence value (Karve et al., 2009; Oleen-Burkey et al.,
2011; Watanabe et al., 2013). These statistical methods present
some limits as they do not include the major factors affecting
adherence and they do not take into account the fact that
the relationships between adherence and clinical endpoints
may not always be linear. Thus, MPR and PDC are concepts,
which provide statistically calculated threshold values but their
clinical validity should be confirmed using other approaches. For
example, one often neglected aspect is the variable nature of
adherence over time as mentioned above. Finally, these analyses
do not assess the specific thresholds of drug or drug classes but
rather the clinical impact of poor adherence to a global treatment.
Finally, when considering only one threshold (for example 80%),
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these analyses do not envisage that they may differ substantially
from one disease to another.
Taken together, these observations on the ability to define
adherence thresholds using large administrative or health care
databases suggest that these records have the advantage of
collecting data from very large unselected groups of patients over
a long period of time. They can produce interesting information
on drug prescriptions and withdrawals, and therefore on the
long-term persistence with the various drug classes. These
datasets represent also unique opportunities to analyze the
relationship between the adherence pattern and hard clinical
outcome parameters such as stroke, cardiovascular events
of death since they are connected to the patients’ clinical
history. Yet, they provide only a rough estimate of how much
medication adherence is necessary to obtain the expected
clinical benefits of a therapy. This limitation is due essentially
to the fact that neither MPR nor PDC make use of the
patients’ dosing history. In the future, newer technologies
enabling to acquire dosing histories coupled electronically
to clinical data (see below) might overcome some of the
limitations of MPR and PDC. The development of more complex
statistical models, with the addition of new metrics reflecting
the multiple facets of the adherence phenomenon, may also
help improving the assessment of valid thresholds using MPR
or PDC.
DEFINING AN ADHERENCE
THRESHOLD USING DATA COLLECTED
BY ELECTRONIC MONITORING OF
ADHERENCE
The development of the MEMS in the 1970s was a major
breakthrough in the field of adherence. Indeed, for the first time,
it became possible to follow a patient’s medication adherence
on a day-to-day basis, and hence to obtain dosing histories for
long periods. To date, more than 750 scientific papers have
been published using this methodology, involving more than
one million trial subjects. Conceptually, electronic monitoring of
drug adherence is also an indirect measure of adherence, as one
cannot assure that once the bottle is opened, the dose is taken.
However, studies have confronted the MEMS data with plasma
drug concentrations and 97% accuracy was found between drug
concentrations and openings of the monitor and time of ingestion
of the prescribed dose. This suggests that the instances where the
pillbox is opened and the drug not taken are relatively exceptional
(Vrijens and Urquhart, 2014). Therefore, today, one can consider
the use of the MEMS as the gold standard to measure adherence.
However, other systems become available, such as the Proteus
Digital Health system, which enable to catch simultaneously the
complete dosing history and the proof that the drug was ingested
(Belknap et al., 2013; DiCarlo et al., 2016). The system consists
on an ingestible nanosensors incorporated in the pill during the
manufacturing process. Once ingested, the sensor is activated in
the stomach and generates a message coded for the medication
name and dose that is transmitted to a wearable patch and then
to a designated device. This new system may be very helpful
to describe more adequately the long-term relationship between
adherence and clinical outcomes. However, as of today, there are
not enough data available to discuss it in more details in this
paper.
Nevertheless, with the use of the MEMS in clinical studies and
clinical practice, we have learnt enormously on the multiple facets
of medication adherence that may affect the determination of
adherence thresholds. In the field of hypertension, these include:
the high variability of adherence patterns within and between
individuals, the inconsistency of the relationship between drug
adherence and clinical endpoints such as blood pressure control,
the variable pharmacological profile of antihypertensive drugs
and particularly the inconsistent relationships between plasma
drug levels and clinical effects. These different issues will be
discussed below.
Adherence Is a Dynamic Process
The first lesson learnt from analyses of the dosing histories is that
drug intake is extremely variable in all clinical conditions and that
adherence is a dynamic process, which one cannot summarize
with a single figure. Indeed, adherence can be perfect during a
certain period and erratic during another one. Deviations from
the prescribed regimen are very frequent and are characterized by
isolated or sequential omissions, drug holidays or compensatory
overdosing (Burnier et al., 2013). This means that to define a
threshold, the pattern of drug omissions should be taken into
account. Averaging different periods of good and poor adherence
might be of interest, but the meaning of such averages to
establish a threshold would need more validations. The element
of variability in non-adherence patterns over time increases the
complexity of defining a valid cut-off point using traditional
regression analyses, which never include such component in the
list of relevant variables.
Relationship Between Adherence and
Outcome
In hypertension, one can correlate the level adherence with
the reduction in blood pressure (BP) or the occurrence of
cardiovascular complications or death. There have been several
attempts to characterize the relationship between drug adherence
and the reduction of BP or the number of subjects reaching
the recommended target BP, with the hope to demonstrate that
the better the adherence to antihypertensive therapy, the lower
the BP. However, in general, these analyses were not done with
the main goal to define adherence thresholds. In 2004, Wetzels
et al. (2004) made an excellent review of about 30 studies, which
analyzed this aspect in hypertension using the MEMS system to
quantify drug adherence. Results were quite disappointing with a
high heterogeneity, some authors finding a significant correlation
between BP reductions or BP control and the level of adherence
(Vaur et al., 1999; Wetzels et al., 2004) and some not (Mallion
et al., 1996). Moreover, even when a correlation was found, this
latter was rather weak. Interestingly, a significant dose-response
was observed when data were analyzed according to predefined
categories of adherence, whereas no correlation was found when
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data were categorized according to categories of achieved BP
(Wetzels et al., 2004). Results were different depending on the
clinical characteristics of the hypertensive population. Thus, in
a group of patients with resistant hypertension receiving at least
a triple therapy, the percentage of patients with an achieved
diastolic BP < 90 mmHg was lowest in patients having an
adherence rate between 51 and 92%, when patients were analyzed
by tertiles to define the cut-off below which BP was uncontrolled
(Burnier et al., 2001; Figure 2). These findings suggest that, in
resistant hypertension, the threshold is not at 80% as initially
anticipated but rather at >92%. In contrast, in another set of
60 treated hypertensive patients who did not respond to a bi-
therapy, one could not observed a difference in adherence level
between patients who reached the BP targets of <140/90 mmHg
and those who improved but did not normalized their BP and
those who did not modify their BP (Bertholet et al., 2000).
These contrasting results may be explained in several ways.
Firstly, adherence to therapy improves as soon as it is measured
(Hawthorne effect). Patients participating in studies receive
a greater attention, which increases their adherence, thereby
blunting the difference between the studied groups. Secondly,
in hypertension, none of the drugs enables to control BP in
100% of subjects, even if the adherence is perfect. Thirdly,
the dose-response curve of most antihypertensive drugs, except
loop diuretics, is rather flat. Therefore, the impact of non-
adherence on BP is often confounded by poor responses to
the prescribed drugs and the absence of dose-response. In
fact, when assessing the relationship between adherence and
BP control, four patterns can occur: patients may be fully
adherent with a good BP response or fully adherent with a
poor BP response, if drug therapy is inadequate. However,
some patients may be poorly adherent with still a good BP
response, for example if they are over-treated, or non-adherent
with no BP response. This indicates once again that individual
patterns play an important role and may limit the ability to
define an adherence cut-off point. Fourthly, in most studies
reviewed by Wetzels et al. (2004), subjects were receiving several
antihypertensive drugs. Therefore, the analyses examined the
threshold of adherence to a treatment strategy rather than to a
given drug.
Impact of the Pharmacological Profile on
the Correlation Between Adherence and
Outcome
The pharmacological profile of drugs (absorption, distribution,
metabolism, and excretion) has a major impact on the
relationship between the level of adherence and clinical
outcomes. Indeed, the impact of missed doses or transient
discontinuations on clinical outcomes is influenced by the dose-
response curve of the prescribed drug, its duration of action,
and its metabolism. For example, in an analysis comparing
three antihypertensive drugs with different half-lives, we have
demonstrated that drugs with a longer duration of action have
a better profile to reduce the risk of complications in patients
with hypertension when adherence is suboptimal (Burnier
et al., 2011). It has also been possible to demonstrate, using
specifically designed protocols, that drugs with a longer duration
of action such as amlodipine or aliskiren attenuate the impact of
missed doses on BP (Leenen et al., 1996; Palatini et al., 2010).
Consequently, multiple isolated drug omissions with these agents
might have little if any influence on clinical endpoints. These
latter studies demonstrate not only the important role of drugs’
duration of action on clinical outcomes when patients are poorly
adherent, but also that it is possible to design specific clinical
protocols to answer a simple, but clinically relevant, question
such as “what is the impact of missed doses ?”
Other drug properties and/or patients’ characteristics may
play a critical role in the possibility to define an adherence
threshold. One of them is the pharmacogenetic profile
influencing the metabolism and elimination of drugs. Thus,
in a recently published study, we compared the inhibition
of platelet aggregation induced by three different anti-P2Y12
drugs, clopidogrel, prasugrel, and ticagrelor, in relation to
drug adherence measured with the MEMS in 120 patients
with coronary heart diseases and a coronary stent (Forni Ogna
et al., 2017). In this study, mean adherence was very high
with all three compounds, respectively, 100, 100, and 96% for
clopidogrel, prasugrel, and ticagrelor. However, at 6 months,
the degree of inhibition of platelet aggregation, measured using
the VASP-PRI, was very different, respectively, 17.7 ± 11.0%
with ticagrelor, 29.2 ± 15.5% with prasugrel and 47.2 ± 17.6%
with clopidogrel. With clopidogrel, platelet inhibition was
unpredictable and extremely variable, independently of the
patients’ adherence. Indeed, the main determinant of the clinical
response to clopidogrel was the CYP2C19 genotype (Forni Ogna
et al., 2016). Consequently, in patients receiving clopidogrel,
adherence correlated with the VASP inhibition only in those
patients carrying defined CYP2C19 genotypes. This observation
further illustrates the complexity of defining a global threshold
that may be valid for all individuals.
Of course, the best situation to characterize an adherence
threshold is when there is a close correlation between plasma
drug levels and clinical endpoints. This is the case, for example,
of immunosuppressive agents in transplantation or drugs in
HIV therapy, clinical situations in which therapeutic drug
monitoring is performed, but definitively not in hypertension.
Thus, in HIV therapy, Paterson et al. (2000) assessed the
effects of different levels of adherence to therapy on virologic,
immunologic, and clinical outcomes in 99 patients treated
with a protease inhibitor. Adherence, measured with the
MEMS, was significantly associated with successful virologic
outcome and increase in CD4 lymphocyte count. However,
the most important observation made in this study is that
virologic failure occurred significantly less in patients with
adherence of 95% or greater (22% failures) than in those
with 80–94.9% adherence (61% failures), and those with less
than 80% adherence (80% failures). These data suggested that
the adherence threshold necessary to obtain the full treatment
benefits is very high in this patients’ population. A similar
observation was done in patients with resistant hypertension
(Burnier et al., 2001).
Another example is the use of adalimumab in the treatment
of patients with psoriasis, rheumatoid arthritis or inflammatory
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FIGURE 2 | Achieved diastolic blood pressure (BP) according to compliance tertiles in patients with resistant hypertension. Achieved 12 h daytime ambulatory
diastolic blood pressure according to tertiles of compliance during the first 2 months of compliance monitoring (ANOVA: F = 3.52, P = 0.039). ∗P < 0.05 versus
tertile 1. Adapted from Bertholet et al. (2000).
bowel diseases. In this case, serum levels of adalimumab have
been reported to correlate with clinical outcomes such as
remission of inflammatory bowel disease or a reduction in
articular symptoms in patients with rheumatoid arthritis, with
4.9 mg/L as the therapeutic threshold of adalimumab serum
concentration (Bartelds et al., 2007; Roblin et al., 2014). In a small
study involving 7 patients with moderate to severe psoriasis, a
pharmacokinetic model has been applied to serum drug levels in
relation to adherence data obtained with the MEMS (Morrison
et al., 2015). With this approach, the authors have demonstrated
that it is possible to define objectively a threshold for adherence
based on a therapeutic drug serum level and MEMS data, thus
avoiding the use of an arbitrary cutoff. A recent analysis of
6048 patients treated with adalimumab for inflammatory bowel
diseases supports this hypothesis (Govani et al., 2018). In this
patient group, the optimal threshold was 86%, as defined with the
MPR.
In hypertension, this approach is much more difficult to
apply because the relationship between plasma drug levels
and the therapeutic outcome – i.e., the reduction of BP –
is usually weak. Thus, in 1980 already, Waeber et al. (1980)
demonstrated that there is a large discrepancy between the
sustained antihypertensive effect of captopril and its short
duration of inhibition of the angiotensin converting enzyme, as
an indirect marker of circulating drug levels. With angiotensin
receptor blockers, we have also demonstrated that protein
binding and the affinity for the angiotensin AT1 receptor are
important determinants of the BP lowering effect of these drugs
(Maillard et al., 2001). Thus, the amount of drug bound to the
AT1 receptor is more relevant than plasma drug levels to explain
the antihypertensive efficacy of these compounds. Therefore, with
this type of drugs, the determination of a therapeutic threshold
based on plasma drug levels is difficult as will be the definition of
an adherence cut-off value.
CONCLUSION
Taken together, these studies demonstrate that dosing histories,
obtained with the use of an electronic monitoring system, might
improve our ability to define adherence thresholds for various
drug therapies. In some circumstances, electronic monitoring of
adherence may be superior to calculation of the PDC or MPR,
but in other situations, it is still insufficient. One example is
the assessment of the relationship between adherence and hard
clinical endpoints such as cardiovascular events and death in
hypertension or dyslipidemia. Indeed, many studies performed
with the MEMS in these indications were of too short duration
to conclude on hard end-points. Yet, when the MEMS is
used in phase 2/3 clinical trials, it is a very potent tool to
link adherence to outcomes and this has been demonstrated
essential in the development of HIV drugs (Tolley et al., 2010).
Today, none of the available methods to measure adherence
seems to be fully adequate to determine adherence cut-offs
but this may change in the future with the availability of
the Proteus Digital Health system, which provides the dosing
history and the proof of ingestion, provided long-terms studies
are conducted with this system. Besides the reliability of the
adherence measurements, one major challenge remains the
large variability of pharmacological parameters within patients’
populations. In fact, very few clinical and pharmacological studies
have examined prospectively the adherence threshold below
which a drug may clearly become ineffective. Today, when the
dose-response relationship of a new compound is investigated,
drug adherence is rarely taken into account because investigators
assume that adherence is perfect in phase 2 and 3 studies, an
assumption, which may not necessarily be correct (Burnier and
Wuerzner, 2015). In our opinion, adequate adherence measures
should be included in all steps of drug development. Today this
can be done easily either with the MEMS or with the Proteus
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Digital Health system. The FDA has accepted these systems
for such purposes. These methods may even be combined
with the determination of plasma or urinary drug levels,
which have been shown to be useful for example in the
management of resistant hypertension (Hamdidouche et al.,
2017).
One should also consider designing specific prospective
protocols to evaluate adherence thresholds, as it was done to
assess the impact of missed doses. In these protocols, the study
population should be as homogenous as possible to provide
reliable and applicable answers. Adherence measures should be
considered as critical parameters and statistical plans should
include analyses according to the level of adherence as a
continuous variable. Statistical models should be ameliorated to
capture the impact of the multiple factors affecting adherence,
as discussed previously. Adherence-adjusted analyses offer the
potential for more powerful tests and better understanding of trial
data and their clinical implications including the determination
of adherence thresholds. Pre-randomization factors associated
with good trial-related product adherence should be identified
and adherence-adjusted analyses be considered early in the
planning of clinical trials. The rapid development of new
technologies like devices, connectivity and analytics, and the
further development of healthcare databases will probably
help finding new solutions to improve our capacity to
answer complex questions such as “how much adherence is
enough.” Thus, there will be a lot of interesting new clinical
research to conduct, which will enable to fly with better
instruments!
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